Patent · US Active

Prodrugs of Naltrexone, Nalmefene and derivatives thereof

US11130771B2 · kind B2 · utility

0Cited by
0References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 20, 2019
Grant dateSep 28, 2021
Priority date
Expiry dateJun 20, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07F9/2404
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.